Insider · CIK 0001780113

Harris Erik

Reports to the SEC for 4 companies · NOVATO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001780113

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-04-16	RAREUltragenyx Pharmaceutical Inc.A Award	EVP & Chief Commercial Officer	AAward	+28.9K sh	—	—	118,410
2026-04-16	RAREUltragenyx Pharmaceutical Inc. · Stock Option (Right to Buy)A Award	EVP & Chief Commercial Officer	AAward	+50K sh	—	—	49,960
2026-03-02	RAREUltragenyx Pharmaceutical Inc.S Sale	EVP & Chief Commercial Officer	SSale	−10.5K sh	$22.80	−$240K	89,515
2026-03-01	RAREUltragenyx Pharmaceutical Inc.A Award	EVP & Chief Commercial Officer	AAward	+11.6K sh	—	—	99,498
2025-11-19	RZLTRezolute, Inc.A Award	Director	AAward	+21K sh	—	—	21,000
2025-11-19	RZLTRezolute, Inc. · Director Stock Option (Right to Buy)A Award	Director	AAward	+12K sh	—	—	12,000
2025-03-25	RZLTRezolute, Inc. · Director Stock Option (Right to Buy)A Award	Director	AAward	+60K sh	—	—	60,000
2025-03-03	RAREUltragenyx Pharmaceutical Inc.S Sale	EVP & Chief Commercial Officer	SSale	−15.1K sh	$42.10	−$636K	87,855
2025-03-01	RAREUltragenyx Pharmaceutical Inc.A Award	EVP & Chief Commercial Officer	AAward	+16.8K sh	—	—	83,976
2025-03-01	RAREUltragenyx Pharmaceutical Inc.A Award	EVP & Chief Commercial Officer	AAward	+18.4K sh	—	—	102,419
2025-03-01	RAREUltragenyx Pharmaceutical Inc. · Stock Option (Right to Buy)A Award	EVP & Chief Commercial Officer	AAward	+30.2K sh	—	—	30,246
2024-10-03	Inozyme Pharma, Inc.Stock Option (right to buy)A Award	Director	AAward	+56K sh	—	—	56,000
2024-05-31	DNLIDenali Therapeutics Inc.A Award	Director	AAward	+5,967 sh	—	—	17,052
2024-05-31	DNLIDenali Therapeutics Inc. · Stock Option (right to buy)A Award	Director	AAward	+17.9K sh	—	—	17,901
2024-03-01	RAREUltragenyx Pharmaceutical Inc.A Award	EVP & Chief Commercial Officer	AAward	+19.4K sh	—	—	70,681
2024-03-01	RAREUltragenyx Pharmaceutical Inc.A Award	EVP & Chief Commercial Officer	AAward	+957 sh	—	—	71,638
2024-03-01	RAREUltragenyx Pharmaceutical Inc.S Sale	EVP & Chief Commercial Officer	SSale	−4,768 sh	$53.76	−$256K	67,163
2024-03-01	RAREUltragenyx Pharmaceutical Inc. · Stock Option (Right to Buy)A Award	EVP & Chief Commercial Officer	AAward	+34.2K sh	—	—	34,200
2023-09-05	RAREUltragenyx Pharmaceutical Inc.S Sale	EVP & Chief Commercial Officer	SSale	−6,000 sh	$37.96	−$228K	51,281
2023-06-19	RAREUltragenyx Pharmaceutical Inc.S Sale	EVP & Chief Commercial Officer	SSale	−305 sh	$48.20	−$14.7K	57,281
2023-06-01	DNLIDenali Therapeutics Inc.A Award	Director	AAward	+4,216 sh	—	—	11,085
2023-06-01	DNLIDenali Therapeutics Inc. · Stock Option (right to buy)A Award	Director	AAward	+12.6K sh	—	—	12,649
2023-03-01	RAREUltragenyx Pharmaceutical Inc.A Award	EVP & Chief Commercial Officer	AAward	+2,663 sh	—	—	38,823
2023-03-01	RAREUltragenyx Pharmaceutical Inc.A Award	EVP & Chief Commercial Officer	AAward	+22K sh	—	—	60,823
2023-03-01	RAREUltragenyx Pharmaceutical Inc.S Sale	EVP & Chief Commercial Officer	SSale	−3,664 sh	$45.25	−$166K	57,344
2023-03-01	RAREUltragenyx Pharmaceutical Inc. · Stock Option (Right to Buy)A Award	EVP & Chief Commercial Officer	AAward	+39.4K sh	—	—	39,400
2022-06-19	RAREUltragenyx Pharmaceutical Inc.S Sale	EVP & Chief Commercial Officer	SSale	−295 sh	$54.78	−$16.2K	36,160
2022-03-01	RAREUltragenyx Pharmaceutical Inc.S Sale	EVP & Chief Commercial Officer	SSale	−2,713 sh	$66.62	−$181K	22,317
2022-03-01	RAREUltragenyx Pharmaceutical Inc.A Award	EVP & Chief Commercial Officer	AAward	+14K sh	—	—	36,317
2022-03-01	RAREUltragenyx Pharmaceutical Inc. · Stock Option (Right to Buy)A Award	EVP & Chief Commercial Officer	AAward	+24.9K sh	—	—	24,900
2022-02-03	DNLIDenali Therapeutics Inc.A Award	Director	AAward	+6,869 sh	—	—	6,869
2022-02-03	DNLIDenali Therapeutics Inc. · Stock Option (right to buy)A Award	Director	AAward	+20.6K sh	—	—	20,607
2021-10-14	RAREUltragenyx Pharmaceutical Inc.S Sale	EVP & Chief Commercial Officer	SSale	−303 sh	$81.14	−$24.6K	25,030
2021-07-06	RAREUltragenyx Pharmaceutical Inc.S Sale	EVP & Chief Commercial Officer	SSale	−375 sh	$91.53	−$34.3K	25,333
2021-06-21	RAREUltragenyx Pharmaceutical Inc.S Sale	EVP & Chief Commercial Officer	SSale	−572 sh	$94.96	−$54.3K	25,708
2021-06-19	RAREUltragenyx Pharmaceutical Inc.S Sale	EVP & Chief Commercial Officer	SSale	−437 sh	$94.63	−$41.4K	26,280
2021-05-07	RAREUltragenyx Pharmaceutical Inc.S Sale	EVP & Chief Commercial Officer	SSale	−393 sh	$113.67	−$44.7K	26,717
2021-05-06	RAREUltragenyx Pharmaceutical Inc.S Sale	EVP & Chief Commercial Officer	SSale	−307 sh	$113.68	−$34.9K	27,110
2021-04-20	RAREUltragenyx Pharmaceutical Inc.S Sale	EVP & Chief Commercial Officer	SSale	−396 sh	$104.28	−$41.3K	27,417
2021-03-02	RAREUltragenyx Pharmaceutical Inc.S Sale	EVP & Chief Commercial Officer	SSale	−707 sh	$138.16	−$97.7K	27,813
2021-03-01	RAREUltragenyx Pharmaceutical Inc.A Award	EVP & Chief Commercial Officer	AAward	+5,500 sh	—	—	26,354
2021-03-01	RAREUltragenyx Pharmaceutical Inc.A Award	EVP & Chief Commercial Officer	AAward	+4,636 sh	—	—	30,990
2021-03-01	RAREUltragenyx Pharmaceutical Inc.S Sale	EVP & Chief Commercial Officer	SSale	−2,470 sh	$138.17	−$341K	28,520
2021-03-01	RAREUltragenyx Pharmaceutical Inc. · Stock Option (Right to Buy)A Award	EVP & Chief Commercial Officer	AAward	+11K sh	—	—	11,000
2020-10-14	RAREUltragenyx Pharmaceutical Inc.S Sale	EVP & Chief Commercial Officer	SSale	−220 sh	$88.00	−$19.4K	23,370
2020-07-06	RAREUltragenyx Pharmaceutical Inc.F Tax Payment	EVP & Chief Commercial Officer	FTax Payment	−260 sh	$86.75	−$22.6K	23,590
2020-06-19	RAREUltragenyx Pharmaceutical Inc.F Tax Payment	EVP & Chief Commercial Officer	FTax Payment	−303 sh	$78.22	−$23.7K	23,850
2020-06-03	RAREUltragenyx Pharmaceutical Inc.S Sale	EVP & Chief Commercial Officer	SSale	−2,516 sh	$74.69	−$188K	20,854
2020-05-06	RAREUltragenyx Pharmaceutical Inc.F Tax Payment	EVP & Chief Commercial Officer	FTax Payment	−209 sh	$66.26	−$13.8K	24,153
2020-04-19	RAREUltragenyx Pharmaceutical Inc.F Tax Payment	EVP & Chief Commercial Officer	FTax Payment	−210 sh	$58.57	−$12.3K	24,362

Recent filings

Accepted (ET)
Apr 204
Harris Erik0001193125-26-164267
SEC(opens sec.gov)
Mar 34
Harris Erik0001193125-26-089282
SEC(opens sec.gov)
Nov 214
Harris Erik0000912282-25-001286
SEC(opens sec.gov)
Mar 264
Harris Erik0000912282-25-000333
SEC(opens sec.gov)
Mar 44
Harris Erik0000950170-25-032773
SEC(opens sec.gov)
Oct 74
Harris Erik0000950170-24-113249
SEC(opens sec.gov)
Jun 44
Harris Erik0001714899-24-000134
SEC(opens sec.gov)
Mar 54
Harris Erik0000950170-24-026629
SEC(opens sec.gov)
Sep 64
Harris Erik0001209191-23-048491
SEC(opens sec.gov)
Jun 214
Harris Erik0001209191-23-038885
SEC(opens sec.gov)

Companies

Address

60 LEVERONI COURT

NOVATO, CA, 94949